Meeting
2022 ASCO Annual Meeting
Quality-adjusted time without symptoms or toxicities (Q-TWiST) analysis of ZUMA-7, a randomized controlled trial of axicabtagene ciloleucel versus standard of care for second-line large B-cell lymphoma.
Authors
Marie José Kersten
Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands
Marie José Kersten , Yao Qiao , Ruchit Shah , Caitlyn Solem , Julia Snider , Christina Ann To , Paul Cheng , Clare Spooner , Miguel-Angel Perales
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track
Hematologic Malignancies
Sub Track
Non-Hodgkin Lymphoma
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 7555)
DOI
10.1200/JCO.2022.40.16_suppl.7555
Abstract #
7555
Poster Bd #
208
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Association of pretreatment (preTx) tumor characteristics and clinical outcomes following second-line (2L) axicabtagene ciloleucel (axi-cel) versus standard of care (SOC) in patients (pts) with relapsed/refractory (R/R) large B-cell lymphoma (LBCL).
First Author: Frederick L. Locke
Poster
2020 ASCO Virtual Scientific Program
Haemophagocytic lymphohistiocytosis (HLH) in patients with large B-cell lymphoma treated with standard of care (SOC) axicabtagene ciloleucel (Axi-cel).
First Author: Sairah Ahmed
Poster
2023 ASCO Annual Meeting
Circulating tumor DNA (ctDNA) by clonoSEQ to monitor residual disease after axicabtagene ciloleucel (axi-cel) in large B-cell lymphoma (LBCL).
First Author: Brodie Miles
Poster
2023 ASCO Annual Meeting
Randomized phase 3 study of tarlatamab, a DLL3-targeting bispecific T-cell engager (BiTE), compared to standard of care in patients with relapsed small cell lung cancer (DeLLphi-304).
First Author: Luis G. Paz-Ares